REDWOOD CITY, Calif., March 07, 2023 (GLOBE NEWSWIRE) — PROCEPT® BioRobotics Company right this moment introduced Aquablation Remedy acquired a MedTech Innovation Briefing (MIB) from the Nationwide Institute for Well being Care Excellence (NICE), for benign prostate hyperplasia (BPH) in the UK. NICE has acknowledged Aquablation Remedy is as efficient as transurethral resection of the prostate (TURP) for the elimination of prostate tissue for males with BPH. A panel of medical consultants mentioned the expertise is revolutionary in comparison with the usual of care and affords extra advantages, resembling elevated means to protect sexual operate. The medical consultants related to the assessment said that the expertise has the potential to interchange TURP and can problem holmium laser enucleation for bigger prostates.
Aquablation remedy is the primary and solely robotic surgical system to obtain a MIB. MIBs are designed to assist decision-making by well being care professionals concerning the adoption and impression of latest expertise by means of detailed technical, medical and financial assessments. New expertise is chosen on the premise of excessive demand on the subject, the potential for helpful medical outcomes, and whether or not proof is accessible.
Mr. Neil Barber, one of many Briefings’ Medical Consultants and a PROCEPT BioRobotics consulting doctor, said, “Now we have been treating males efficiently with Aquablation remedy for over seven years and imagine it can quickly grow to be the usual of look after BPH. Sufferers in the end need their work, leisure, and intercourse lives again with out risking long-term catheterization or lack of sexual operate. AquaBeam’s actual time picture steerage permits surgeons to see a affected person’s anatomy by means of a multidimensional view, permitting for a completely personalized remedy plan. The robotic executes the remedy plan and guides the waterjet with pace and accuracy resulting in a extra constant, predictable, and safer affected person final result. Furthermore, it’s a lot simpler to coach new urologists to grow to be proficient utilizing Aquablation remedy, which bodes properly for the longer term.”
“The NICE MedTech Innovation Briefing additional validates the worth we imagine Aquablation Remedy brings to sufferers, docs, hospitals and healthcare methods around the globe,” mentioned Sham Shiblaq, Govt Vice President, Chief Industrial Officer of PROCEPT® BioRobotics. “The strong physique of medical proof exhibits Aquablation remedy affords improved security and sturdiness when in comparison with transurethral resection of the prostate, which is the present gold customary surgical remedy choice.”
About PROCEPT BioRobotics Company
PROCEPT BioRobotics is a surgical robotics firm centered on advancing affected person care by growing transformative options in urology. PROCEPT BioRobotics develops, manufactures and sells the AquaBeam Robotic System, a complicated, image-guided, surgical robotic system to be used in minimally invasive urologic surgical procedure with an preliminary deal with treating benign prostatic hyperplasia, or BPH. BPH is the commonest prostate illness and impacts roughly 40 million males in america. PROCEPT BioRobotics designed Aquablation remedy to ship efficient, secure and sturdy outcomes for males affected by decrease urinary tract signs, or LUTS, as a result of BPH which might be impartial of prostate measurement and form or surgeon expertise. The Firm has developed a major and rising physique of medical proof, which incorporates 9 medical research and over 150 peer-reviewed publications, supporting the advantages and medical benefits of Aquablation remedy.
Ahead Wanting Statements
This launch comprises ahead‐wanting statements inside the which means of federal securities legal guidelines, together with with respect to the Firm’s projected monetary efficiency for full 12 months 2022, statements concerning the potential utilities, values, advantages and benefits of Aquablation® remedy carried out utilizing PROCEPT BioRobotics’ merchandise, together with AquaBeam® Robotic System, which contain dangers and uncertainties that might trigger the precise outcomes to vary materially from the anticipated outcomes and expectations expressed in these forward-looking statements. You might be cautioned to not place undue reliance on these forward-looking statements. Ahead-looking statements are solely predictions based mostly on our present expectations, estimates, and assumptions, legitimate solely as of the date they’re made, and topic to dangers and uncertainties, a few of which we aren’t at present conscious. Ahead-looking statements might embrace statements concerning monetary steerage, market alternative and penetration, the Firm’s potential or assumed future outcomes of operations, together with descriptions of the Firm’s revenues, gross margin, profitability, working bills, put in base development, industrial momentum, total enterprise or the general macroeconomic atmosphere, which can impression buyer spending or the Firm’s prices. Ahead‐wanting statements shouldn’t be learn as a assure of future efficiency or outcomes and will not essentially be correct indications of the instances at, or by, which such efficiency or outcomes will probably be achieved. These ahead‐wanting statements are based mostly on the Firm’s present expectations and inherently contain vital dangers and uncertainties. Precise outcomes and the timing of occasions might differ materially from these anticipated in such ahead‐wanting statements on account of these dangers and uncertainties. These dangers and uncertainties are described extra absolutely within the part titled “Threat Elements” within the Firm’s filings with the Securities and Change Fee (the “SEC”), together with the Firm’s annual report on Type 10-Okay filed with the SEC on February 28, 2023. PROCEPT BioRobotics doesn’t undertake any obligation to replace ahead‐wanting statements and expressly disclaims any obligation or enterprise to launch publicly any updates or revisions to any ahead‐wanting statements contained herein. These forward-looking statements shouldn’t be relied upon as representing PROCEPT BioRobotics’ views as of any date subsequent to the date of this press launch.
Vital Security Info
All surgical remedies have inherent and related unwanted side effects. For a listing of potential unwanted side effects go to https://aquablation.com/safety-information/.
Investor Contact:
Matt Bacso, CFA
VP, Investor Relations and Enterprise Operations
[email protected]
